Celgene Receives a Hold from Barclays

By Austin Angelo

Barclays analyst Geoff Meacham maintained a Hold rating on Celgene (NASDAQ: CELG) on July 27 and set a price target of $135. The company’s shares closed yesterday at $134.10, close to its 52-week high of $139.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 8.5% and a 58.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Achillion Pharmaceuticals.

Celgene has an analyst consensus of Strong Buy, with a price target consensus of $152.15.

The company has a one year high of $139 and a one year low of $96.93. Currently, Celgene has an average volume of 3.98M.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Last month, Michael D. Casey, a Director at CELG sold 9,250 shares for a total of $1,230,713.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.